Clinical Trials Using EGFR/HER2 Inhibitor AP32788

Clinical trials are research studies that involve people. The clinical trials on this list are studying EGFR/HER2 Inhibitor AP32788. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

    The purpose of this study is to compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
    Location: 10 locations

  • A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC)

    The purpose of this phase 1 / 2 study is to evaluate the safety, recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs), maximum tolerated dose (MTD), pharmacokinetics of oral TAK-788 and its active metabolites, anti-tumor activity of TAK-788 in participants with NSCLC with epidermal growth factor receptor (EGFR) or human epidermal growth factor 2 (HER2) mutations, explore relationship between tumor and / or plasma biomarkers and TAK-788 efficacy, safety, and / or cytochrome P450 (CYP) 3A induction (in Part 1 [Dose Escalation Component] and Part 2 [Expansion Cohorts] for oral TAK-788) and (in Part 1A [Dose Escalation Combination Component] when TAK-788 is taken in combination with pemetrexed / carboplatin), and anti-tumor activity of TAK-788 in participants with solid tumors other than NSCLC with EGFR or HER2 mutations in Parts 1 and 2.
    Location: 6 locations